Daiwa Securities Group’s AbCellera Biologics ABCL Stock Holding History

Daiwa Securities Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.45M	Buy	+311,500	New	+$1.52M	﹤0.01%	653
2026 Q1	–	Sell	-1,151	Closed	-$4K	–	1177
2025 Q4	$4K	Hold	1,151	–	–	﹤0.01%	1248
2025 Q3	$6K	Hold	1,151	–	–	﹤0.01%	1185
2025 Q2	$4K	Hold	1,151	–	–	﹤0.01%	1161
2025 Q1	$3K	Hold	1,151	–	–	﹤0.01%	1158
2024 Q4	$3K	Hold	1,151	–	–	﹤0.01%	1184
2024 Q3	$3K	Hold	1,151	–	–	﹤0.01%	1193
2024 Q2	$3K	Hold	1,151	–	–	﹤0.01%	1221
2024 Q1	$5K	Hold	1,151	–	–	﹤0.01%	1200
2023 Q4	$7K	Hold	1,151	–	–	﹤0.01%	1184
2023 Q3	$5K	Hold	1,151	–	–	﹤0.01%	1150
2023 Q2	$7K	Hold	1,151	–	–	﹤0.01%	1153
2023 Q1	$9K	Hold	1,151	–	–	﹤0.01%	1113
2022 Q4	$12K	Buy	1,151 +91	+9%	+$1.05K	﹤0.01%	1103
2022 Q3	$10K	Hold	1,060	–	–	﹤0.01%	1124
2022 Q2	$11K	Buy	1,060 +238	+29%	+$2.02K	﹤0.01%	1135
2022 Q1	$8K	Hold	822	–	–	﹤0.01%	1146
2021 Q4	$12K	Buy	+822	New	+$12.5K	﹤0.01%	1139

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Daiwa Securities Group's ABCL Position: Q2 2026 in Review

Daiwa Securities Group opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 311,500 shares worth $2.45M. The stake represents ﹤0.01% of the portfolio and ranks #653 among its holdings. This is a return to the name: Daiwa Securities Group previously reported a position in ABCL as recently as Q4 2025.

Daiwa Securities Group first reported a position in ABCL in Q4 2021 and has held it in 18 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Daiwa Securities Group held 311,500 shares of AbCellera Biologics worth $2.45M as of Q2 2026.
AbCellera Biologics was a new Daiwa Securities Group position in Q2 2026.
AbCellera Biologics made up ﹤0.01% of Daiwa Securities Group's portfolio in Q2 2026, its #653 holding.
Daiwa Securities Group first reported a position in AbCellera Biologics in Q4 2021 and has held it in 18 quarters since.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.